Fertility sparing surgery for stage IA type I and G2 endometrial cancer in reproductive-aged patients: evidence-based approach and future perspectives

Updates Surg. 2017 Mar;69(1):29-34. doi: 10.1007/s13304-017-0419-y. Epub 2017 Feb 10.

Abstract

Fertility-sparing surgery (FSS) in reproductive-age patients affected by endometrial cancer (EC) gained growing attention in the last decade, although the first reports were already published in 1990-2000s. Nevertheless, only few patients undergoing FSS for stage I, type I EC had been reported in each case series, without a robust multicenter study. In the available literature there are even fewer reported cases of conservative treatment of Stage IA and G2 EC. Considering these important gaps in our current knowledge, the purpose of this review was to summarize the available evidence about conservative treatments for stage IA type I and G2 EC, to improve the pretreatment counseling for reproductive-age patients. According to our overview, women who have low-risk disease (G1 or G2, endometrioid histotype confined to the endometrium) are candidates for progestin therapy. In addition, FSS could be considered a valid option for reproductive-aged patients with stage IA type I and G2 EC. Nevertheless, we solicit new trials to clarify the medium- and long-term outcomes in this kind of patients.

Keywords: Endometrial cancer; Fertility-sparing surgery; Outcomes; Progestins; Reproduction.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Counseling
  • Endometrial Neoplasms / surgery*
  • Evidence-Based Medicine
  • Female
  • Fertility*
  • Humans
  • Progestins / administration & dosage

Substances

  • Progestins